within Pharmacolibrary.Drugs.ATC.V;

model V09IA04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.002,
    k12             = 0.1,
    k21             = 0.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09IA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Technetium (99mTc) votumumab is a radiopharmaceutical composed of the monoclonal antibody votumumab labeled with the radioisotope technetium-99m (99mTc). It was developed for tumor imaging, particularly targeting tumor necrosis and specific cancer antigens in diagnostic nuclear medicine. The drug was intended for use in cancer imaging, but is not widely approved or in mainstream clinical use today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available for technetium (99mTc) votumumab. The following PK parameters are estimated based on general properties of radiolabeled monoclonal antibodies administered intravenously for imaging purposes in adults.</p><h4>References</h4><ol><li><p>Shanthly, N, et al., &amp; Thakur, ML (2006). 99mTc-Fanolesomab: affinity, pharmacokinetics and preliminary evaluation. <i>The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...</i> 50(2) 104–112. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16770300/\">https://pubmed.ncbi.nlm.nih.gov/16770300</a></p></li><li><p>Huston, JS, et al., &amp; Weiner, LM (1996). Single-chain Fv radioimmunotargeting. <i>The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)</i> 40(3) 320–333. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8961808/\">https://pubmed.ncbi.nlm.nih.gov/8961808</a></p></li><li><p>Decristoforo, C, &amp; Mather, SJ (2002). The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides. <i>The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)</i> 46(3) 195–205. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12134136/\">https://pubmed.ncbi.nlm.nih.gov/12134136</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09IA04;
